Fennec Pharmaceuticals (FRX) Stock Statistics & Valuation Metrics

Fennec Pharmaceuticals has a market cap or net worth of C$335.84M. The enterprise value is C$115.70M.

Fennec Pharmaceuticals has 27,618,744 shares outstanding. The number of shares has decreased by -2.65% in one year.

Fennec Pharmaceuticals’s return on equity (ROE) is 0.07 and return on invested capital (ROIC) is 41.47%.

The current PE Ratio of Fennec Pharmaceuticals is -308.19. Fennec Pharmaceuticals’s PEG ratio is -0.30.

In the last 12 months, Fennec Pharmaceuticals had revenue of 47.54M and earned -436.00K in profits. Earnings per share was -0.02.

In the last 12 months, operating cash flow was 26.98M and capital expenditures 0.00, giving a free cash flow of 26.98M billion.

Fennec Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Fennec Pharmaceuticals upcoming earnings date is Aug 7, 2025, TBA (Confirmed).

Fennec Pharmaceuticals as a current ratio of 6.38, with Debt / Equity ratio of -969.21%

In the past 12 months, Fennec Pharmaceuticals has paid 365.00K in taxes.

Fennec Pharmaceuticals EV to EBITDA ratio is 26.49, with an EV/FCF ratio of 4.71.

Fennec Pharmaceuticals has C$26.63M in cash and marketable securities with $19.34M in debt, giving a net cash position of -C$7.29M billion.

Gross margin is 94.40%, with operating margin of 5.40%, and net profit margin of -0.92%.

The average price target for Fennec Pharmaceuticals is C$18.60, which is 11.43% higher than the current price. The consensus rating is Strong Buy